Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer

Review proposal consultation

Stakeholder matrix (PDF 219 KB)

Lung cancer (non small cell, EGFR mutation positive) - afatinib: Equality impact assessment - guidance development

Lung cancer (non small cell, EGFR mutation positive) - afatinib: final appraisal determination information

Lung cancer (non small cell, EGFR mutation positive) - afatinib: final appraisal determination document

Lung cancer (non small cell, EGFR mutation positive) - afatinib: final appraisal determination document (PDF 366 KB)

Lung cancer (non small cell, EGFR mutation positive) - afatinib: evaluation report information

Lung cancer (non small cell, EGFR mutation positive) - afatinib: final scope

Lung cancer (non small cell, EGFR mutation positive) - afatinib: final matrix

Lung cancer (non small cell, EGFR mutation positive) - afatinib: response to consultee and commentator comments on the draft scope and provisional matrix

Lung cancer (non small cell, EGFR mutation positive) - afatinib: Equality Impact Assessment - scoping

Lung cancer (non small cell, EGFR mutation positive) - afatinib: provisional matrix - (pre referral)

Lung cancer (non small cell, EGFR mutation positive) - afatinib: draft scope - (pre referral)